Reig Jofre submits results note on the fourth quarter of 2020
REIG JOFRE closed 2020 with a turnover of €230 million and achieved a Consolidated Profit of €5.7 million, with growth of 15% in both figures
In a year affected by the impact of COVID-19, Reig Jofre grows at double digits and starts a technology transfer project that will allow the manufacture of the Vaccine candidate developed by Janssen Pharmaceutical.
At the close of 2020, turnover stood at over €230 million, some 15% ahead of 2019. Full integration of the new Osteoarticular product portfolio, acquired in July 2019, international growth and sales of essential medicines have compensated for the loss of income from other products as a result of the COVID-19 crisis.
REIG JOFRE’s three divisions show positive growth in turnover, and have generated strategies to adapt to the new environment created by COVID-19 without compromising medium and long-term plans.